{"id":"W4318301860","doi":"10.1016/j.jtho.2022.09.125","title":"OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; Medicine; T790M; Adjuvant; Internal medicine; Oncology; Lung cancer; Placebo; Cancer; Erlotinib; Epidermal growth factor receptor; Pathology; Gefitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003129708,0.0008760668,0.002529776,0.001025667,0.0002218153,0.002240829,0.0008869467,0.0007875953,0.002563386],"category_scores_gemma":[0.002596728,0.0004114445,0.003271278,0.001498322,0.0003877837,0.001008216,0.0004653585,0.001763359,0.0007830096],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001987882,"about_ca_system_score_gemma":0.001947917,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006341836,"about_ca_topic_score_gemma":0.02345663,"domain_scores_codex":[0.9990956,0.0002062349,0.0001606036,0.0001157219,0.0002763109,0.0001455896],"domain_scores_gemma":[0.9981018,0.0006384978,0.0005463925,0.000105546,0.00041134,0.0001964829],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.03356445,0.001223196,0.0390563,0.008421691,0.01226797,0.0002592273,0.0001621677,0.003708114,0.004723591,0.001037641,0.0509452,0.8446305],"study_design_scores_gemma":[0.02755197,0.02681904,0.38168,0.009982731,0.07346599,0.001644109,0.0003730452,0.002920373,0.006922599,0.001677082,0.466588,0.0003749903],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.2734911,0.6343026,0.002085011,0.01218426,0.004654969,0.000797884,0.02810991,0.0002230399,0.04415124],"genre_scores_gemma":[0.5230627,0.3748269,0.006363029,0.01831363,0.005278809,0.001042209,0.05503655,0.0002922789,0.0157838],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.006341836,"threshold_uncertainty_score":0.01655167,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02533324856646252,"score_gpt":0.4374827494442849,"score_spread":0.4121495008778224,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}